



醫院管理局
HOSPITAL
AUTHORITY

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Jan 2022 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Adalimumab	Hyrimoz	Musculoskeletal and joint disease	Pending	Pending further information
2	Alirocumab	Praluent	Cardiovascular system	Rejected	Major budget impact
3	Brentuximab Vedotin	Adcetris	Malignant disease and immunosuppression	Pending	Pending further information
4	Brigatinib	Alunbrig	Malignant disease and immunosuppression	Approved	
5	Capmatinib	Tabrecta	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
6	Dapagliflozin	Forxiga	Cardiovascular system	Pending	Pending further information
7	Docetaxel	Taxotere	Malignant disease and immunosuppression	Approved	
8	Eftrenonacog alfa	Alprolix	Cardiovascular system	Approved	
9	Fentanyl citrate	PecFent	Central nervous system	Pending	Pending further information
10	Indacaterol / glycopyrronium / mometasone furoate	Energair Breezhaler	Respiratory system	Approved	
11	Infliximab	Remicade	Gastro-intestinal system	Rejected	Major budget impact
12	Insulin glargine	Toujeo	Endocrine system	Rejected	Alternative(s) available in HADF with comparable benefits
13	Linacotide	Linzess	Gastro-intestinal system	Approved	
14	Lorlatinib	Lorviqua	Malignant disease and immunosuppression	Pending	Pending further information
15	Lutropin Alfa	Luveris	Endocrine system	Approved	
16	Methoxyflurane	Penthrox	Anaesthesia	Rejected	Alternative(s) available in HADF with comparable benefits
17	Niraparib	Zejula	Malignant disease and immunosuppression	Approved	
18	Olaparib	Lynparza	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
19	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
20	Riociguat	Adempas	Cardiovascular system	Approved	
21	Silodosin	Urief	Obstetrics, gynaecology, and urinary-tract disorders	Rejected	Alternative(s) available in HADF with comparable benefits
22	Tofacitinib	Xeljanz	Gastro-intestinal system	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.